GR-2001
/ Genrix Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 10, 2024
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
(clinicaltrials.gov)
- P3 | N=582 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P3 trial • Infectious Disease • Tetanus
March 12, 2024
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults
(clinicaltrials.gov)
- P1/2 | N=202 | Completed | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1/2 trial • Infectious Disease • Tetanus
1 to 2
Of
2
Go to page
1